DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Analyst Earnings Estimates
NASDAQ:DAWN - Nasdaq - US23954D1090 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 131.161M | 152.7M 16.42% | 225.27M 47.52% | 376.85M 67.29% | 485.29M 28.78% | 671.43M 38.36% | 766.15M 14.11% | 872.71M 13.91% | 982.5M 12.58% | |||
| EBITDA YoY % growth | -146.85M -101.94% | -205.681M -40.06% | -215.241M -4.65% | -168.512M 21.71% | -121.952M 27.63% | -14.306M 88.27% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -146.91M -101.97% | -206.064M -40.27% | -217.27M -5.44% | -163.055M 24.95% | -109.443M 32.88% | 38.782M 135.44% | 135.77M 250.09% | 279.06M 105.54% | 409.3M 46.67% | 489.14M 19.51% | 573.37M 17.22% | |
| Operating Margin | N/A | N/A | -165.65% | -106.78% | -48.58% | 10.29% | 27.98% | 41.56% | 53.42% | 56.05% | 58.36% | |
| EPS YoY % growth | -2.17 36.64% | -2.38 -9.68% | -1.78 25.21% | -1.41 20.98% | -0.85 39.32% | 0.24 128.49% | 1.04 327.98% | 2.01 93.63% | 2.37 17.72% | 2.84 19.78% | 3.31 16.52% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.34 7.99% | -0.33 47.80% | -0.30 13.54% | -0.13 54.28% | -0.07 79.03% | 0.15 144.27% |
| Revenue Q2Q % growth | 40.913M 103.85% | 46.633M 59.70% | 54.72M 77.89% | 65.673M 93.67% | 74.302M 81.61% | 85.955M 84.32% |
| EBITDA Q2Q % growth | -32.64M -205.61% | -26.52M 58.11% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -38.503M -229.92% | -37.551M 42.52% | -31.324M 23.73% | -15.331M 62.60% | -9.59M 75.09% | 9.708M 125.85% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.29 -480.00% | -0.36 | 0.07 | 20.33% |
| Q1 2025 Q2Q % growth | -0.35 51.39% | -0.45 | 0.10 | 22.45% |
| Q4 2024 Q2Q % growth | -0.64 | -0.37 | -0.27 | -73.33% |
| Q3 2024 Q2Q % growth | -0.37 31.48% | -0.42 | 0.05 | 11.53% |
| Q2 2024 Q2Q % growth | -0.05 91.80% | -0.77 | 0.72 | 93.47% |
| Q1 2024 Q2Q % growth | -0.72 -22.03% | -0.68 | -0.04 | -6.41% |
| Q4 2023 Q2Q % growth | -0.64 -14.29% | -0.59 | -0.05 | -7.56% |
| Q3 2023 Q2Q % growth | -0.54 -1.89% | -0.61 | 0.07 | 12.11% |
| Q2 2023 Q2Q % growth | -0.61 -1.67% | -0.62 | 0.01 | 1.98% |
| Q1 2023 Q2Q % growth | -0.59 -22.92% | -0.60 | 0.01 | 2.33% |
| Q4 2022 Q2Q % growth | -0.56 -55.56% | -0.58 | 0.02 | 3.12% |
| Q3 2022 Q2Q % growth | -0.53 -60.61% | -0.54 | 0.01 | 2.70% |
| Q2 2022 Q2Q % growth | -0.60 88.10% | -0.50 | -0.10 | -20.66% |
| Q1 2022 Q2Q % growth | -0.48 | -0.39 | -0.09 | -22.23% |
| Q4 2021 Q2Q % growth | -0.36 | -0.36 | 0.00 | 1.28% |
| Q3 2021 Q2Q % growth | -0.33 | -0.29 | -0.04 | -15.44% |
| Q2 2021 Q2Q % growth | -5.04 | -0.32 | -4.72 | -1,468.63% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 33.91M 313.94% | 36.007M | -2.097M | -5.82% |
| Q1 2025 Q2Q % growth | 30.761M | 30.842M | -81K | -0.26% |
| Q4 2024 Q2Q % growth | 29.2M | 28.348M | 852K | 3.01% |
| Q3 2024 Q2Q % growth | 20.07M | 24.016M | -3.946M | -16.43% |
| Q2 2024 Q2Q % growth | 8.192M | 1.042M | 7.15M | 686.18% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -1.6% | 12.15% | 0% | 11.61% |
| Revenue | -1.74% | -5.7% | -1.32% | -3.98% |